KTB Network

Founded 1981


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 36
Average round size
The average size of a deal this fund participated in
Portfolio companies 36
Rounds per year 0.90
Lead investments 9
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 4
Key employees 10

Areas of investment

  • Biotechnology
  • Health Care
  • Video
  • Software
  • Therapeutics

The company was established in Asia in South Korea. The main office of represented VC is situated in the Seongnam.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the KTB Network, startups are often financed by Softbank Ventures Asia, Samsung Ventures, Formation 8. The meaningful sponsors for the fund in investment in the same round are Stonebridge Capital, Softbank Ventures Asia, Samsung Ventures. In the next rounds fund is usually obtained by Industrial Bank of Korea, Capstone Partners Co., Ltd., Stonebridge Capital.

Among the most popular fund investment industries, there are Internet, Advertising Platforms. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Toss, Berkeley Lights, Mogoroom. For fund there is a match between the country of its foundation and the country of its the most frequent investments - South Korea.

The top amount of exits for fund were in 2007. This KTB Network works on 25 percentage points less the average amount of lead investments comparing to the other organizations. The fund is generally included in less than 2 deals every year. Speaking about the real fund results, this VC is 18 percentage points more often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2015. Despite it in 2019 the fund had an activity.

We also calculated 10 valuable employees in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of KTB Network:
Typical Co-investors
KTB Network is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after KTB Network:

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation


Social Network
Social Shopping
$44M12 Jul 2021 Bengaluru India Karnataka

Task Management
$4M11 Jan 2021 Gyeonggi-do South Korea

XW Laboratories

Health Care
$40M18 Sep 2020 China Hubei Jiang'an District


Social Network
Social Shopping
$11M17 Aug 2020 Bengaluru India Karnataka


$14M18 Jun 2020 Gyeonggi-do South Korea


Social Network
Social Shopping
$4M03 Mar 2020 Bengaluru India Karnataka

$4M06 Jan 2020 Gyeonggi-do South Korea


Social Network
Social Shopping
04 Nov 2019 Bengaluru India Karnataka

Orum Therapeutics

Health Care
$30M17 Jul 2019 Gyeonggi-do South Korea
GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021

– GenEdit has closed a $26m Series A financing.
– New investors include Eli Lilly, KTB Network, Company K Partners, Korea Investment Partners, DAYLI Partners, KB Investment, IMM Investment, and TIMEFOLIO Asset Management.
– The funding will support the further development of GenEdit’s NanoGalaxy™ platform of non-viral, non-lipid polymer nanoparticles, and the selection for clinical development of therapeutic candidates targeting diseases of the nervous system.

PharmCADD Raised USD 16m in Series B Funding

– PharmCADD announced that it has finished USD 16m series B funding on March 31, 2021.
– This funding round was led by Strategic Investors: Huons, Samyang Holdings and SD BIOSENSOR; and Financial Investors: KTB Network, Daily Partners, DSC Investment, KDB Capital, Maple Investment and KB Securities.
– As a result, PharmCADD has secured total of USD 22m in funding since its establishment.
– PharmCADD plans to use the funding not only to launch the U.S. and India-based branches but also to advance its AI & Physics-based drug discovery platform technology, Pharmulator™, and to expand R&D manpower. The funding will be used for the preclinical study of internal pipelines as well.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent KTB Network?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: